| ||||||||||||||||||||||||||||||
Today’s Big NewsMay 21, 2024In pharma tax probe, Sen. Wyden puts Pfizer in hot seat with CEO letter AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D AstraZeneca, on fast track of growth, sets revenue target at $80B by 2030 Who distrusts the FDA? Survey shows gender, location and politics are key factors J&J study shows 25% of pulsed field ablation procedures performed with zero X-ray guidance Exscientia cuts a quarter of staff while preserving AI-generated pipeline Lab at center of Zantac saga claims GSK hid drug’s risks for decades
Featured
Top StoriesBy James Waldron AstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy strategy, CEO Pascal Soriot told investors as he set out a bold ambition to almost double global revenues to $80 billion by 2030.AstraZeneca, on fast track of growth, sets revenue target at $80B by 2030By Kevin Dunleavy After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030.Who distrusts the FDA? Survey shows gender, location and politics are key factorsBy Nick Paul Taylor A survey has shown the demographics most likely to be distrustful of the FDA. The results suggest the agency needs to win the trust of conservative women in rural communities who are in poor health or dissatisfied with their healthcare.
By Conor Hale Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation approach for treating atrial fibrillation, which was submitted for FDA review earlier this year.Exscientia cuts a quarter of staff while preserving AI-generated pipelineBy Annalee Armstrong Exscientia is initiating “efficiency measures” to save cash, which will include a workforce reduction of around a quarter of staff while preserving the AI drug hunter’s existing pipeline.Lab at center of Zantac saga claims GSK hid drug’s risks for decadesBy Zoey Becker A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then.Novartis standbys Cyndi Lauper, Michelle Bernstein unite to report Cosentyx is 'Still Working'By Andrea Park Nearly a decade into Cosentyx’s tenure as an FDA-approved treatment for plaque psoriasis and psoriatic arthritis, Novartis has tapped two of its go-to celebrity spokespeople to confirm that the drug is still working for them.Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signalBy Nick Paul Taylor Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets.Lilly pads case for mirikizumab in its next potential indication in Crohn's diseaseBy Fraiser Kansteiner Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immunology approval.Labcorp unveils first-trimester blood test for detecting preeclampsia risksBy Conor Hale The test is designed to be performed between 11 and 14 weeks into pregnancy and delivers a risk score for developing the condition before 34 weeks.HCPs conflicted on corporate messaging, but some admit its influenceBy Nick Paul Taylor The pharma industry is still in HCPs’ good books, with 61% of physicians polled by CMI saying they have a favorable view of drugmakers. But the question of how companies can use corporate brand marketing to promote and enhance their image is more vexed given HCPs’ mixed views on the subject.GSK's SWIFT trial anthology shows long-acting treatment reduces asthma attacksBy Gabrielle Masson It’s not a double album release, but a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have both shown GSK's long-acting asthma treatment reduces attacks.No treachery here: Celltrion signs 'The Traitors' star Mollie Pearce for bowel disease campaignBy Ben Adams South Korean biosimilar company Celltrion is signing up Mollie Pearce, a contestant on the British TV show “The Traitors,” to help front its latest “Where’s Crohn’s & Colitis?” campaign.
Fierce podcasts Don’t miss an episode
ResourcesWhitepaper Comprehensive Cell Solutions: Focus on Cellular Therapy CollectionsPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.Sponsored by: Comprehensive Cell Solutions Whitepaper In Vitro Antibodies – Next-Gen Science Delivers Optimized CandidatesLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.Sponsored by: Specifica, a Q2 Solutions company Whitepaper Branded Digital Companions in BiopharmaThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.Presented by: Blue Matter, strategic consultants in the life sciences eBook Designing Patient-Centered Endpoint in Rare Disease TrialsTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.Sponsored by: Emmes Company
Industry EventsOn Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK
Upcoming Fierce Events
View all events | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
